133 related articles for article (PubMed ID: 31423335)
41. Interventions for preventing postpartum constipation.
Turawa EB; Musekiwa A; Rohwer AC
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD011625. PubMed ID: 26387487
[TBL] [Abstract][Full Text] [Related]
42. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.
Cryer B; Katz S; Vallejo R; Popescu A; Ueno R
Pain Med; 2014 Nov; 15(11):1825-34. PubMed ID: 24716835
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.
Sloots CE; Rykx A; Cools M; Kerstens R; De Pauw M
Dig Dis Sci; 2010 Oct; 55(10):2912-21. PubMed ID: 20428949
[TBL] [Abstract][Full Text] [Related]
44. Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation.
Webster L; Diva U; Tummala R; Sostek M
Pain Pract; 2018 Apr; 18(4):505-514. PubMed ID: 28898536
[TBL] [Abstract][Full Text] [Related]
45. First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis.
Peacock WF; Slatkin NE; Israel RJ; Stambler N
J Emerg Med; 2022 Feb; 62(2):231-239. PubMed ID: 34893381
[TBL] [Abstract][Full Text] [Related]
46. Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with lung cancer.
Imai H; Fumita S; Harada T; Noriyuki T; Gamoh M; Okamoto M; Akashi Y; Kizawa Y; Tokoro A
Jpn J Clin Oncol; 2021 Mar; 51(3):444-450. PubMed ID: 33157554
[TBL] [Abstract][Full Text] [Related]
47. Lubiprostone for Opioid-Induced Constipation Does Not Interfere with Opioid Analgesia in Patients with Chronic Noncancer Pain.
Spierings EL; Brewer RP; Rauck RL; Losch-Beridon T; Mareya SM
Pain Pract; 2017 Mar; 17(3):312-319. PubMed ID: 26990171
[TBL] [Abstract][Full Text] [Related]
48. Naldemedine: A New Option for OIBD.
Coluzzi F; Scerpa MS; Pergolizzi J
J Pain Res; 2020; 13():1209-1222. PubMed ID: 32547183
[TBL] [Abstract][Full Text] [Related]
49. Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation.
Vijayvargiya P; Camilleri M; Vijayvargiya P; Erwin P; Murad MH
Aliment Pharmacol Ther; 2020 Jul; 52(1):37-53. PubMed ID: 32462777
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review.
Mehta N; O'Connell K; Giambrone GP; Baqai A; Diwan S
Postgrad Med; 2016; 128(3):282-9. PubMed ID: 26839023
[TBL] [Abstract][Full Text] [Related]
51. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
Gordon M; Naidoo K; Akobeng AK; Thomas AG
Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
[TBL] [Abstract][Full Text] [Related]
52. Drugs for Treating Opioid-Induced Constipation: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials.
Sridharan K; Sivaramakrishnan G
J Pain Symptom Manage; 2018 Feb; 55(2):468-479.e1. PubMed ID: 28919541
[TBL] [Abstract][Full Text] [Related]
53. New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.
Sanders M; Jones S; Löwenstein O; Jansen JP; Miles H; Simpson K
Pain Med; 2015 Aug; 16(8):1540-50. PubMed ID: 26110375
[TBL] [Abstract][Full Text] [Related]
54. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
[TBL] [Abstract][Full Text] [Related]
55. Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone.
Webster LR; Israel RJ
J Pain Res; 2018; 11():2509-2516. PubMed ID: 30425563
[TBL] [Abstract][Full Text] [Related]
56. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.
Pergolizzi JV; Christo PJ; LeQuang JA; Magnusson P
Drug Des Devel Ther; 2020; 14():1009-1025. PubMed ID: 32210534
[TBL] [Abstract][Full Text] [Related]
57. Peripherally acting μ-opioid antagonist for the treatment of opioid-induced constipation: Systematic review and meta-analysis.
Nishie K; Yamamoto S; Yamaga T; Horigome N; Hanaoka M
J Gastroenterol Hepatol; 2019 May; 34(5):818-829. PubMed ID: 30597600
[TBL] [Abstract][Full Text] [Related]
58. Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.
Streicher JM; Bilsky EJ
J Pharm Pract; 2018 Dec; 31(6):658-669. PubMed ID: 28946783
[TBL] [Abstract][Full Text] [Related]
59. Methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients. Results from the MOTION trial.
Patel PB; Brett SJ; O'Callaghan D; Anjum A; Cross M; Warwick J; Gordon AC
Intensive Care Med; 2020 Apr; 46(4):747-755. PubMed ID: 32016532
[TBL] [Abstract][Full Text] [Related]
60. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
